GRI Bio, Inc. (GRI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GRI
- Company GRI Bio, Inc.
- Price $0.54
- Changes Percentage 0.38
- Change 0.002
- Day Low $0.53
- Day High $0.57
- Year High $21.06
- Year Low $0.3
- Market Cap $4,824,020
- Price Avg 50 EMA (D) $0.74
- Price Avg 200 EMA (D) $1.72
- Exchange NASDAQ
- Volume 121,239
- Average Volume 303,800
- Open $0.55
- Previous Close $0.53
- EPS 77.53
- PE 0.01
- Earnings Announcement 2025-03-26 20:00:00
- Shares Outstanding $8,933,370
Company brief: GRI BIO, INC. (GRI )
- Healthcare
- Biotechnology
- Dr. W. Marc Hertz Ph.D.
- https://www.gribio.com
- US
- N/A
- 02-10-2021
- US3622AW2059
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.